|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Hypotheses were formulated regarding enhanced erlotinib response in preclinical models harboring the patient tumor somatic variant MAPK1 E322K following the identification of tumor somatic variants.
|
26181029 |
2015 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Our discovery of a synthetic lethal interaction of cetuximab in combination with MEK1/2 inhibition for the NRAS mutant subgroup of mCRC underscores the importance of therapeutic intervention both in the MEK-ERK and EGFR pathways to achieve maximal therapeutic efficacy against NRAS-mutant mCRC tumors.
|
27636997 |
2016 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Adamantinoma-like Ewing sarcoma (ALES) is a rare tumor that demonstrates the EWSR1-FLI1 translocation characteristic of Ewing sarcoma despite overt epithelial differentiation including diffuse expression of cytokeratins and p40.
|
30285997 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Thyroid cancers with BRAF mutation are preferentially sensitive to MEK inhibitors, whereas tumors with other MEK-ERK effector pathway gene mutations have variable responses, either because they are only partially dependent on ERK and/or because feedback responses elicit partial refractoriness to MEK inhibition.
|
18381570 |
2008 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In the case of BRAF-V600E mutant melanoma, ERK inhibition has emerged as a viable clinical approach to abrogate signaling through the ERK pathway, even in cases where MEK and Raf inhibitor treatments fail to induce tumor regression due to resistance mechanisms.
|
31190430 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Therapeutically targetable activating mutations in MAPK/ERK signaling pathway genes, including MAPK1 and BRAF, were detected in 20% of tumors.
|
30977242 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In a BRAF(V600E)-containing xenograft model of human melanoma, orally administered dabrafenib inhibited ERK activation, downregulated Ki67, and upregulated p27, leading to tumor growth inhibition.
|
23844038 |
2013 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Association analyses between the 800 candidate SNPs (covering 82 genes) and pain in a patient cohort of 1368 patients with HNSCC (206 patients with severe pain vs. 1162 with non-severe pain) showed the highest significance for MAPK1/ERK2, a gene belonging to the MAP kinase family (rs8136867, p value = 8.92 × 10(-4); odds ratio [OR] = 1.33, 95 % confidence interval [CI]: 1.13-1.58).
|
26872611 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
TCIP-H SCCHN tumors were associated with the MAPK/ERK, JAK/STAT and mTOR/AKT signaling pathways, and were enriched in CASP8, EP300, EPHA2, HRAS mutations, CD274, PDCD1LG2, JAK2 amplifications.
|
31422218 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.200 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Multiple Sclerosis
|
0.160 |
GeneticVariation
|
disease |
GWASDB |
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
|
21833088 |
2011 |
|
Multiple Sclerosis
|
0.160 |
GeneticVariation
|
disease |
GWASCAT |
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
|
21833088 |
2011 |
|
Multiple Sclerosis
|
0.160 |
GeneticVariation
|
disease |
BEFREE |
Interleukin (IL)-12 is thought to play an important role in the development of atherosclerosis and recently, polymorphism of the 3'-untranslated region of the IL-12 p40 gene (A1188C) was reported to be associated with diabetes and multiple sclerosis.
|
15988104 |
2005 |
|
Multiple Sclerosis
|
0.160 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
|
24076602 |
2013 |
|
Microcephaly
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
Patients with a deletion that also encompassed the MAPK1 gene, located just distal to LCR22-D, have a different and more severe phenotype, characterized by a higher prevalence of congenital heart anomalies, growth restriction and microcephaly.
|
25123976 |
2014 |
|
Transitional cell carcinoma of bladder
|
0.110 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Paraffin-embedded sections of 146 CIN lesions (32 CIN I, 49 CIN II, and 43 CIN III) and 22 invasive cervical carcinomas (13 squamous and 9 adenocarcinomas) were used for the standard immunohistochemical procedure with the application of the ERK2 monoclonal antibody.
|
17961162 |
2008 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interleukin (IL)-12 is thought to play an important role in the development of atherosclerosis and recently, polymorphism of the 3'-untranslated region of the IL-12 p40 gene (A1188C) was reported to be associated with diabetes and multiple sclerosis.
|
15988104 |
2005 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interleukin (IL)-12 is thought to play an important role in the development of atherosclerosis and recently, polymorphism of the 3'-untranslated region of the IL-12 p40 gene (A1188C) was reported to be associated with diabetes and multiple sclerosis.
|
15988104 |
2005 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The extent of Hsp27 phosphorylation at its Ser15, Ser78 and Ser82 residues were further evaluated with site-specific antibodies in tumor samples by tissue lysate array- and tissue microarray-based analyses, and in the BT474 breast cancer cell line treated with heregulin alpha1 (HRG alpha1) or the p38 MAPK inhibitor, SB203580.
|
17697330 |
2007 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MAPK12 (P ARTP = 0.05) was only associated with breast cancer-specific mortality, and MAP3K1 (P ARTP = 0.02) and MAPK1 (P ARTP = 0.05) were only associated with all-cause mortality.
|
24993294 |
2014 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Similarly, carriers of 20 SNPs in PIK3R1, AKT1/2, and MAPK1 genes (signaling pathways-genetic variants) had different associations with breast cancer between strata, and the proportion of the SNP-cancer relationship explained by traits varied 45-50% between the strata.
|
28478612 |
2017 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DUSP4 and MAPK8 interacted with calories to alter breast cancer risk; MAPK1 interacted with DOBS, dietary fiber, folate, and BMI; MAP3K2 interacted with dietary fat; and MAPK14 interacted with dietary folate and BMI.
|
25629224 |
2015 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, mutations in exon 2 of MEK1 and exon 7 of ERK2 have not been investigated in these cancers although they are occasionally found in some other cancers or cell lines.
|
19411838 |
2009 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Experimental results on male BALB/c nude mice confirmed that orally administration of COP at high-dose (150 mg/kg) could suppress tumor growth, and may reduce cancer metastasis risk by inhibiting the RAS-ERK pathway in vivo.
|
28165459 |
2017 |